Regeneron Pharmaceuticals Stock Today
| REGN Stock | USD 823.72 15.13 1.87% |
|
|
Regeneron Pharmaceuticals is selling at 823.72 as of the 1st of December 2023; that is 1.87 percent up since the beginning of the trading day. The stock's open price was 808.59. Regeneron Pharmaceuticals has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Regeneron Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 2nd of October 2023 and ending today, the 1st of December 2023. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 2nd of April 1991 | Category Healthcare | Classification Health Care |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 107.13 M outstanding shares of which 1.4 M shares are at this time shorted by private and institutional investors with about 2.74 trading days to cover. More on Regeneron Pharmaceuticals
Moving together with Regeneron Stock
| + | 0.78 | JNJ | Johnson Johnson | Aggressive Push | PairCorr | |
| + | 0.7 | PFE | Pfizer Inc | Fiscal Quarter End 31st of December 2023 | PairCorr |
Moving against Regeneron Stock
| - | 0.49 | TCRX | Tscan Therapeutics | Upward Rally | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Fiscal Quarter End 31st of December 2023
Regeneron Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Regeneron Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Regeneron Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary, Regeneron Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Regeneron Pharmaceuticals' managers, analysts, and investors.
Environment Score | Governance Score | Social Score |
| President CEO, Director | Leonard Schleifer | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| SEC Filings | Regeneron Pharmaceuticals Security & Exchange Commission EDGAR Reports | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Biotech, Cancer Fighters (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Excise Tax Activities | Animal Testing | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Regeneron Pharmaceuticals report their recommendations after researching Regeneron Pharmaceuticals' financial statements, talking to executives and customers, or listening in on Regeneron Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Regeneron Pharmaceuticals. The Regeneron consensus assessment is calculated by taking the average forecast from all of the analysts covering Regeneron Pharmaceuticals. Buy23 Opinions | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Piotroski F Score Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Regeneron Pharmaceuticals based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Regeneron Pharmaceuticals financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks. HealthyDetails
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Macroaxis Advice The buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Regeneron Pharmaceuticals' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details Strong BuyFairly Valued | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Regeneron Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Regeneron Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. Regeneron Pharmaceuticals' bond ratings measure its overall creditworthiness, which in many ways corresponds to the cost of borrowing for an issuer. These ratings assign a letter grade to all of Regeneron Pharmaceuticals' outstanding corporate bonds that indicate their credit quality. We use reports published by private self-sufficient rating services such as Standard & Poor's or Fitch Ratings Inc. to evaluate a bond issuer's financial strength or its ability to pay a bond's principal and interest. Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Regeneron Pharmaceuticals' financial leverage. It provides some insight into what part of Regeneron Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Regeneron Pharmaceuticals (REGN) is traded on NASDAQ Exchange in USA. It is located in 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707 and employs 12,463 people. Regeneron Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 88.09 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Regeneron Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Regeneron Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Regeneron Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 107.13 M outstanding shares of which 1.4 M shares are at this time shorted by private and institutional investors with about 2.74 trading days to cover.
Regeneron Pharmaceuticals currently holds about 7.02 B in cash with 5.01 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 65.75.
Check Regeneron Pharmaceuticals Probability Of Bankruptcy
OwnershipRegeneron Pharmaceuticals has a total of 107.13 Million outstanding shares. The majority of Regeneron Pharmaceuticals outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Regeneron Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Regeneron Pharmaceuticals. Please pay attention to any change in the institutional holdings of Regeneron Pharmaceuticals as this could imply that something significant has changed or about to change at the company. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.
Ownership Allocation
Check Regeneron Ownership DetailsRegeneron Stock Price Odds Analysis
Contingent on a normal probability distribution, the odds of Regeneron Pharmaceuticals jumping above the current price in 90 days from now is about 35.18%. The Regeneron Pharmaceuticals probability density function shows the probability of Regeneron Pharmaceuticals stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Regeneron Pharmaceuticals has a beta of 0.7816 indicating as returns on the market go up, Regeneron Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Regeneron Pharmaceuticals will be expected to be much smaller as well. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Regeneron Pharmaceuticals is significantly underperforming NYSE Composite.
Based on a normal probability distribution, the odds of Regeneron Pharmaceuticals to move above the current price in 90 days from now is about 35.18 (This Regeneron Pharmaceuticals probability density function shows the probability of Regeneron Stock to fall within a particular range of prices over 90 days) .
Regeneron Pharmaceuticals Historical Income Statement
Regeneron Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Regeneron's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Regeneron Pharmaceuticals revenue and expense. Regeneron Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Regeneron Pharmaceuticals' Direct Expenses is very stable as compared to the past year. As of the 1st of December 2023, Weighted Average Shares is likely to grow to about 116.6 M, while Consolidated Income is likely to drop about 3.6 B. View More FundamentalsRegeneron Stock Against Markets
Picking the right benchmark for Regeneron Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Regeneron Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Regeneron Pharmaceuticals is critical whether you are bullish or bearish towards Regeneron Pharmaceuticals at a given time. Please also check how Regeneron Pharmaceuticals' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Regeneron Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Comparator Now
Portfolio ComparatorCompare the composition, asset allocations and performance of any two portfolios in your account |
| All Next | Launch Module |
Regeneron Pharmaceuticals Corporate Directors
Regeneron Pharmaceuticals corporate directors refer to members of a Regeneron Pharmaceuticals board of directors. The board of directors generally takes responsibility for the Regeneron Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Regeneron Pharmaceuticals' board members must vote for the resolution. The Regeneron Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Charles Baker | Independent Director | Profile | |
| Joseph Goldstein | Independent Director | Profile | |
| Anthony Coles | Independent Director | Profile | |
| George Sing | Independent Director | Profile |
How to buy Regeneron Stock?
Before investing in Regeneron Pharmaceuticals, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Regeneron Pharmaceuticals. To buy Regeneron Pharmaceuticals stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Regeneron Pharmaceuticals. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Regeneron Pharmaceuticals stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Regeneron Pharmaceuticals stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Regeneron Pharmaceuticals stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Regeneron Pharmaceuticals, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Regeneron Stock please use our How to Invest in Regeneron Pharmaceuticals guide.
Already Invested in Regeneron Pharmaceuticals?
The danger of trading Regeneron Pharmaceuticals is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Regeneron Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Regeneron Pharmaceuticals. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Regeneron Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Regeneron Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regeneron Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regeneron Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regeneron Pharmaceuticals Stock: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Complementary Tools for Regeneron Stock analysis
When running Regeneron Pharmaceuticals' price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.24) | Earnings Share 35.09 | Revenue Per Share 122.634 | Quarterly Revenue Growth 0.145 | Return On Assets 0.0921 |
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.